Multiple Myeloma: International Myeloma Foundation : ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

back

ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA

	12.06.11
Be the first to comment Name Email Address URL Remember personal info? Comments (You may use HTML tags for style)	print share \| related articles

Be the first to comment